ATE512973T1 - Nukleosid-arylphosphoramidate und ihre verwendung als antivirale mittel zur behandlung von hepatitis-c-virus - Google Patents
Nukleosid-arylphosphoramidate und ihre verwendung als antivirale mittel zur behandlung von hepatitis-c-virusInfo
- Publication number
- ATE512973T1 ATE512973T1 AT07824684T AT07824684T ATE512973T1 AT E512973 T1 ATE512973 T1 AT E512973T1 AT 07824684 T AT07824684 T AT 07824684T AT 07824684 T AT07824684 T AT 07824684T AT E512973 T1 ATE512973 T1 AT E512973T1
- Authority
- AT
- Austria
- Prior art keywords
- nucleoside
- hepatitis
- virus
- treatment
- arylphosphoramidates
- Prior art date
Links
- 239000002777 nucleoside Substances 0.000 title abstract 3
- 241000711549 Hepacivirus C Species 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 239000003443 antiviral agent Substances 0.000 title 1
- 150000003833 nucleoside derivatives Chemical class 0.000 title 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 abstract 2
- -1 nucleoside compounds Chemical class 0.000 abstract 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract 1
- 229930024421 Adenine Natural products 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 229960000643 adenine Drugs 0.000 abstract 1
- 125000003563 glycoside group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 150000008298 phosphoramidates Chemical class 0.000 abstract 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical group NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 abstract 1
- 125000004437 phosphorous atom Chemical group 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0623493.4A GB0623493D0 (en) | 2006-11-24 | 2006-11-24 | Chemical compounds |
| PCT/GB2007/004480 WO2008062206A2 (en) | 2006-11-24 | 2007-11-23 | Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis c virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE512973T1 true ATE512973T1 (de) | 2011-07-15 |
Family
ID=37636469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07824684T ATE512973T1 (de) | 2006-11-24 | 2007-11-23 | Nukleosid-arylphosphoramidate und ihre verwendung als antivirale mittel zur behandlung von hepatitis-c-virus |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8658616B2 (de) |
| EP (2) | EP2412717A1 (de) |
| JP (1) | JP5271913B2 (de) |
| KR (1) | KR20090114356A (de) |
| CN (1) | CN101547932B (de) |
| AT (1) | ATE512973T1 (de) |
| AU (1) | AU2007323220B2 (de) |
| CA (1) | CA2670328C (de) |
| CO (1) | CO6230992A2 (de) |
| CY (1) | CY1112254T1 (de) |
| DK (1) | DK2097434T3 (de) |
| EC (1) | ECSP099462A (de) |
| ES (1) | ES2368012T3 (de) |
| GB (1) | GB0623493D0 (de) |
| IL (1) | IL198610A (de) |
| MX (1) | MX2009005120A (de) |
| MY (1) | MY145856A (de) |
| NO (1) | NO20092399L (de) |
| NZ (2) | NZ577152A (de) |
| PL (1) | PL2097434T3 (de) |
| PT (1) | PT2097434E (de) |
| RU (1) | RU2464272C2 (de) |
| SG (1) | SG171596A1 (de) |
| SI (1) | SI2097434T1 (de) |
| WO (1) | WO2008062206A2 (de) |
| ZA (1) | ZA200904031B (de) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| PT1576138T (pt) | 2002-11-15 | 2017-05-03 | Idenix Pharmaceuticals Llc | 2'-metil-nucleósidos em combinação com interferão e mutação de flaviviridae |
| GB0623493D0 (en) | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
| US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| EP2307434B1 (de) * | 2008-07-02 | 2014-02-12 | IDENIX Pharmaceuticals, Inc. | Verbindungen und pharmazeutische zusammensetzungen für die behandlung von virusinfektionen |
| PA8855601A1 (es) | 2008-12-23 | 2010-07-27 | Forformidatos de nucleósidos | |
| US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
| US8716263B2 (en) * | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| CA2749394A1 (en) * | 2009-01-09 | 2010-07-15 | University College Of Cardiff Consultants Limited | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| WO2011123668A2 (en) | 2010-03-31 | 2011-10-06 | Pharmasset, Inc. | Stereoselective synthesis of phosphorus containing actives |
| PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
| US8871737B2 (en) | 2010-09-22 | 2014-10-28 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| GB201016855D0 (en) * | 2010-10-06 | 2010-11-17 | Nucana Biomed Ltd | Chemical compounds |
| EP2646453A1 (de) | 2010-11-30 | 2013-10-09 | Gilead Pharmasset LLC | Verbindungen |
| EP2691409B1 (de) | 2011-03-31 | 2018-02-21 | Idenix Pharmaceuticals LLC. | Verbindungen und zusammensetzungen zur behandlung von virusinfektionen |
| AR088441A1 (es) | 2011-09-12 | 2014-06-11 | Idenix Pharmaceuticals Inc | Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales |
| EP2768838A1 (de) | 2011-10-14 | 2014-08-27 | IDENIX Pharmaceuticals, Inc. | Substituierte 3 ', 5 '-cyclophosphate von purin-nukleotid-verbindungen und pharmazeutische zusammensetzungen für die behandlung von virusinfektionen |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| EP2852605B1 (de) | 2012-05-22 | 2018-01-31 | Idenix Pharmaceuticals LLC | 3',5'-cyclische phosphat-prodrugs für hcv-infektion |
| BR112014029115A8 (pt) | 2012-05-22 | 2018-04-03 | Idenix Pharmaceuticals Inc | Composto, composição farmacêutica, e, uso de um composto ou composição |
| EP2852604B1 (de) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclische phosphoramidat-prodrugs für hcv-infektion |
| ES2597757T3 (es) | 2012-05-25 | 2017-01-20 | Janssen Sciences Ireland Uc | Nucleósidos de uracilespirooxetano |
| US9192621B2 (en) | 2012-09-27 | 2015-11-24 | Idenix Pharmaceuticals Llc | Esters and malonates of SATE prodrugs |
| BR112015007698A2 (pt) | 2012-10-08 | 2017-08-22 | Idenix Pharmaceuticals Inc Centre National De La Recherche Scientifique E Univ Montpellier 2 Science | Composto, composição farmacêutica, e, uso de um composto |
| EP2909222B1 (de) | 2012-10-22 | 2021-05-26 | Idenix Pharmaceuticals LLC | 2',4'-verbrückten nukleoside für hcv-infektion |
| ES2627195T3 (es) | 2012-11-16 | 2017-07-27 | University College Cardiff Consultants Limited | Mezcla de RP/SP gemcitabina-[fenil-(bencloxi-l-alaninil)]-fosfato |
| WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| WO2014137926A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
| WO2014137930A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | Thiophosphate nucleosides for the treatment of hcv |
| EP2970357B1 (de) | 2013-03-13 | 2025-01-01 | Idenix Pharmaceuticals LLC | Aminosäure-phosphoramidat-pronukleotide von 2'-cyano-, azido- und aminonukleosiden zur behandlung von hcv |
| EP2981542B1 (de) | 2013-04-01 | 2021-09-15 | Idenix Pharmaceuticals LLC | 2',4'-fluor-nukleoside zur behandlung von hcv |
| RU2015148006A (ru) | 2013-04-12 | 2017-05-18 | Ачиллион Фармасютикалз, Инк. | Дейтерированные нуклеозидные пролекарства, применимые для лечения hcv |
| US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
| EP3027636B1 (de) | 2013-08-01 | 2022-01-05 | Idenix Pharmaceuticals LLC | D-amino acid phosphoramidate pronucleotide of halogenierte pyrimidine verbindungen für leber krankheiten |
| PL3038601T3 (pl) | 2013-08-27 | 2020-08-24 | Gilead Pharmasset Llc | Formulacja złożona dwóch związków przeciwwirusowych |
| CN104447923B (zh) * | 2013-09-23 | 2018-03-30 | 中国药科大学 | 2’‑脱氧‑2’‑氟‑2’‑甲基核苷衍生物及其制备方法与在制药中的用途 |
| WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
| KR102548806B1 (ko) | 2014-11-28 | 2023-06-27 | 뉴카나 피엘씨 | 항암제로서 새로운 2' 및/또는 5' 아미노산 에스테르 포스포르아미데이트 3'-디옥시아데노신 유도체 |
| WO2016144918A1 (en) | 2015-03-06 | 2016-09-15 | Atea Pharmaceuticals, Inc. | β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT |
| US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
| US10711029B2 (en) | 2016-07-14 | 2020-07-14 | Atea Pharmaceuticals, Inc. | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| SG11201901457TA (en) | 2016-09-07 | 2019-03-28 | Atea Pharmaceuticals Inc | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment |
| IL295609B2 (en) | 2017-02-01 | 2023-11-01 | Atea Pharmaceuticals Inc | Nucleotide hemisulfate salt for the treatment of hepatitis C virus |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| CN112351799A (zh) | 2018-04-10 | 2021-02-09 | 阿堤亚制药公司 | 具有硬化的hcv感染患者的治疗 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| WO2021173713A1 (en) | 2020-02-27 | 2021-09-02 | Atea Pharmaceuticals, Inc. | Highly active compounds against covid-19 |
| US20230322823A1 (en) * | 2020-08-18 | 2023-10-12 | University Of Southern California | Promoiety strategy to enhance drug activity |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
| JP2024525164A (ja) | 2021-06-17 | 2024-07-10 | アテア ファーマシューティカルズ， インコーポレイテッド | 有利な抗ｈｃｖ併用療法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5614504A (en) | 1990-08-01 | 1997-03-25 | The University Of South Florida | Method of making inosine monophosphate derivatives and immunopotentiating uses thereof |
| GB9505025D0 (en) | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
| JP4313847B2 (ja) | 1995-04-21 | 2009-08-12 | ユニヴァーシティ オブ サウス フロリダ | 免疫賦活性イノシン一リン酸の５’−ヌクレオチダーゼ抵抗性誘導体およびその使用 |
| US5981507A (en) | 1995-12-14 | 1999-11-09 | Advanced Magnetics, Inc. | Polymeric carriers linked to nucleotide analogues via a phosphoramide bond |
| US5959100A (en) | 1996-03-27 | 1999-09-28 | Nexstar Pharmaceuticals, Inc. | Pyrimidine nucleosides as therapeutic and diagnostic agents |
| CA2326535A1 (en) | 1998-03-27 | 1999-10-07 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
| US6030957A (en) | 1998-06-29 | 2000-02-29 | Wayne Hughes Institute | Aryl phosphate derivatives of d4T having anti-HIV activity |
| US7144874B2 (en) | 2002-10-25 | 2006-12-05 | Parker Hughes Institute | Aryl phosphate derivatives of d4T having activity against resistant HIV strains |
| GB9821058D0 (en) * | 1998-09-28 | 1998-11-18 | Univ Cardiff | Chemical compound |
| WO2001034622A1 (en) | 1999-11-08 | 2001-05-17 | Origenix Technologies, Inc. | Combinatorial library synthesis and pharmaceutically active compounds produced thereby |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| DE60105424T2 (de) | 2000-05-26 | 2005-09-22 | Idenix (Cayman) Ltd. | Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden |
| YU92202A (sh) | 2000-05-26 | 2006-01-16 | Idenix (Cayman) Limited | Metode i smeše za lečenje flavi virusa i pesti virusa |
| JP4413493B2 (ja) | 2000-10-04 | 2010-02-10 | サンタリス ファーマ アー／エス | プリンｌｎａ類似体の改善された合成方法 |
| MY141789A (en) * | 2001-01-19 | 2010-06-30 | Lg Chem Investment Ltd | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same. |
| CN1267446C (zh) | 2001-01-22 | 2006-08-02 | 默克公司 | 作为依赖于rna的rna病毒聚合酶的抑制剂的核苷衍生物 |
| US7563618B2 (en) | 2001-03-23 | 2009-07-21 | Geron Corporation | Oligonucleotide conjugates |
| EP1404694A1 (de) | 2001-06-21 | 2004-04-07 | Glaxo Group Limited | Nukleosidverbindungen in hcv |
| US6962991B2 (en) | 2001-09-12 | 2005-11-08 | Epoch Biosciences, Inc. | Process for the synthesis of pyrazolopyrimidines |
| EP1569652A4 (de) | 2001-12-14 | 2008-07-02 | Pharmasset Inc | N sp 4 /sp acylcytosin-nukleoside zur behandlung von virusinfektionen |
| WO2003051899A1 (en) | 2001-12-17 | 2003-06-26 | Ribapharm Inc. | Deazapurine nucleoside libraries and compounds |
| WO2003061385A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | Tricyclic nucleoside library compounds, synthesis, and use as antiviral agents |
| WO2003062256A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
| US20070032448A1 (en) | 2002-01-17 | 2007-02-08 | Zhi Hong | Sugar modified nucleosides as viral replication inhibitors |
| WO2003068162A2 (en) | 2002-02-14 | 2003-08-21 | Pharmasset Ltd. | Modified fluorinated nucleoside analogues |
| CN1863538A (zh) * | 2002-09-30 | 2006-11-15 | 健亚生物科技公司 | 用于治疗c型肝炎病毒感染的核苷衍生物 |
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| AU2005267421B2 (en) | 2004-06-24 | 2010-06-03 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
| US7261853B2 (en) * | 2004-07-16 | 2007-08-28 | Eagle Mold Company | Decelerated ejector pin system and method for operating the same |
| US20080280842A1 (en) | 2004-10-21 | 2008-11-13 | Merck & Co., Inc. | Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection |
| CA2589935A1 (en) | 2004-12-09 | 2006-06-15 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
| GB0505781D0 (en) * | 2005-03-21 | 2005-04-27 | Univ Cardiff | Chemical compounds |
| TW200720285A (en) * | 2005-04-25 | 2007-06-01 | Genelabs Tech Inc | Nucleoside compounds for treating viral infections |
| WO2006121820A1 (en) * | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
| CN101287472B (zh) | 2005-08-15 | 2011-10-12 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物 |
| CA2637879A1 (en) | 2006-02-14 | 2007-08-23 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| GB0623493D0 (en) | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
| AU2007338899A1 (en) | 2006-12-20 | 2008-07-03 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection |
| EP2124555B1 (de) | 2007-01-05 | 2015-07-08 | Merck Sharp & Dohme Corp. | Nukleosidarylphosphoramidate für die behandlung von rna-abhängigen rna-virusinfektionen |
| WO2008104408A2 (en) | 2007-02-27 | 2008-09-04 | K. U. Leuven Research & Development | Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
-
2006
- 2006-11-24 GB GBGB0623493.4A patent/GB0623493D0/en not_active Ceased
-
2007
- 2007-11-23 EP EP11169876A patent/EP2412717A1/de not_active Withdrawn
- 2007-11-23 WO PCT/GB2007/004480 patent/WO2008062206A2/en not_active Ceased
- 2007-11-23 MY MYPI20091944A patent/MY145856A/en unknown
- 2007-11-23 NZ NZ577152A patent/NZ577152A/en not_active IP Right Cessation
- 2007-11-23 CA CA2670328A patent/CA2670328C/en not_active Expired - Fee Related
- 2007-11-23 SG SG201102856-0A patent/SG171596A1/en unknown
- 2007-11-23 SI SI200730726T patent/SI2097434T1/sl unknown
- 2007-11-23 ES ES07824684T patent/ES2368012T3/es active Active
- 2007-11-23 PT PT07824684T patent/PT2097434E/pt unknown
- 2007-11-23 PL PL07824684T patent/PL2097434T3/pl unknown
- 2007-11-23 JP JP2009537699A patent/JP5271913B2/ja not_active Expired - Fee Related
- 2007-11-23 NZ NZ593712A patent/NZ593712A/xx not_active IP Right Cessation
- 2007-11-23 MX MX2009005120A patent/MX2009005120A/es active IP Right Grant
- 2007-11-23 AU AU2007323220A patent/AU2007323220B2/en not_active Ceased
- 2007-11-23 DK DK07824684.0T patent/DK2097434T3/da active
- 2007-11-23 AT AT07824684T patent/ATE512973T1/de active
- 2007-11-23 US US12/516,253 patent/US8658616B2/en not_active Expired - Fee Related
- 2007-11-23 EP EP07824684A patent/EP2097434B1/de not_active Not-in-force
- 2007-11-23 KR KR1020097013078A patent/KR20090114356A/ko not_active Ceased
- 2007-11-23 RU RU2009123104/04A patent/RU2464272C2/ru not_active IP Right Cessation
- 2007-11-23 CN CN200780045190.7A patent/CN101547932B/zh not_active Expired - Fee Related
-
2009
- 2009-05-06 IL IL198610A patent/IL198610A/en not_active IP Right Cessation
- 2009-06-10 ZA ZA200904031A patent/ZA200904031B/xx unknown
- 2009-06-19 CO CO09064160A patent/CO6230992A2/es active IP Right Grant
- 2009-06-23 EC EC2009009462A patent/ECSP099462A/es unknown
- 2009-06-24 NO NO20092399A patent/NO20092399L/no not_active Application Discontinuation
-
2011
- 2011-09-13 CY CY20111100875T patent/CY1112254T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE512973T1 (de) | Nukleosid-arylphosphoramidate und ihre verwendung als antivirale mittel zur behandlung von hepatitis-c-virus | |
| NZ597544A (en) | Modified 4'-nucleosides as antiviral agents | |
| HRP20050417B1 (hr) | Antiviralni derivati nukleozida | |
| DE602005013922D1 (de) | Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor | |
| TW200630344A (en) | Tetracyclic indole derivatives as antiviral agents | |
| PL366726A1 (en) | 4'-substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus | |
| MY128463A (en) | 4' substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus | |
| ATE496920T1 (de) | Polycyclische mittel zur behandlung von infektionen mit dem respiratory syncytial virus | |
| ATE414520T1 (de) | 3 oder 2 hydroxymethyl substituierte nucleoside derivate und ihre verwendung zur behandlung von virusinfektionen | |
| WO2007020193A3 (en) | Antiviral phosphoramidates of 4 ' -substituted pronucleotides | |
| PE20060837A1 (es) | COMPUESTOS DE 3H-OXAZOLO Y 3H-TIAZOLO[4,5-d]PIRIMIDIN-2-ONA 3,5-DISUSTITUIDA Y 3,5,7-TRISUSTITUIDA Y PROFARMACOS DE LOS MISMOS | |
| WO2006027628A3 (en) | Naphthalimide derivatives as antiviral agents | |
| EA200970375A1 (ru) | Соединения и способы лечения вируса гепатита с | |
| WO2005084315A3 (en) | Pyranoindole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease | |
| TH126308A (th) | สารประกอบ และองค์ประกอบทางเภสัชกรรมสำหรับการบำบัดการติดเชื้อไวรัส | |
| GT200300246A (es) | Derivados antivirales de nucleosidos | |
| TH124666A (th) | สไปโรไซคลิก โพรลีน และการใช้สารเหล่านั้นในการรักษาการติดเชื้อ hcv | |
| UY28110A1 (es) | Derivados de nucleosido antivirales |